semaglutide coming off shortage list On February 21, 2025, the FDA announced that semaglutide, the active ingredient in Ozempic and Wegovy, is no longer considered in shortage, signaling an improvement in national supply. As a result, compounding Ozempic, Wegovy move closer to
Description
The semaglutide reconstitution chart and mixing chart provide additional reference tables for different reconstitution volumes
Long-term side effects of Ozempic can show up in different ways
A loss of muscle mass is counterproductive to what GLP-1 users are trying to accomplish
This adaptive response can slow weight loss despite maintained exercise habits
